A global phase I study of WVE-210201 (dystrophin exon 51) for the treatment of Duchenne muscular dystrophy (DMD)

Trial Profile

A global phase I study of WVE-210201 (dystrophin exon 51) for the treatment of Duchenne muscular dystrophy (DMD)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2017

At a glance

  • Drugs WVE 210201 (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 09 Nov 2017 According to a WaVe life Sciences media release, this study including an open-label extension study are designed to include an interim efficacy readout of dystrophin expression from muscle biopsies in 2H 2019.
    • 06 Nov 2017 According to a WaVe life Sciences media release, data from this study is expected in Q3 2018.
    • 06 Nov 2017 Status changed from planning to recruiting, according to a WaVe life Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top